#ASH24 myeloma, 16/27 patients were successfully tested with WGS on circulating tumor cells. Major question is how much drop out might exist. Still a tour de force by the @ireneghobrial.bsky.social lab

Watch as @ireneghobrial.bsky.social @danafarber.bsky.social dives into groundbreaking insights from longitudinal single-cell studies & #teclistamab outcomes at #ASH24 🎥 Don't miss this #VJHemOnc interview 👉 tinyurl.com/3u7dkrhn @ash-hematology.bsky.social #MultipleMyeloma #MMsm

Decentralized clinical trials. Amazing collaboration with pharma and FDA and academia with ash. #ash24

8 days ago, ASH decided to join Bluesky. 🌤️ So far, we're enjoying fewer distractions & more meaningful connections. 💬 Engaging with our amazing #hematology and #hemeonc communities has never been easier. We created an #ASH24 feed for you & we have more feeds coming soon: bit.ly/ASH24feed #Hemesky

@ireneghobrial.bsky.social #MyelomaSky #HemeSky

1/ Keen to share the story of my postdoc research out in @natureportfolio.bsky.social! We built a massive resource characterizing the spatial landscape of the gut—and yes, we dug deep into the biology too. If you’ve got a minute, let me walk you through the story. 🧵👇 www.nature.com/articles/s41...

Throwback to the editorial we wrote last year celebrating the Ig Nobels. Free-to-read link: rdcu.be/d09QN

This week, Nature Portfolio published a series of research papers from the Human Cell Atlas initiative. Nature profiles some of the key technologies that made them possible. 🧪

Out today in Nature: "The Human Cell Atlas"! In my News and Views, I compare the cell atlas to early naturalists creating an atlas of South America. Researchers mining this cell atlas can now make big discoveries, just as the next naturalists then discovered evolution. www.nature.com/articles/d41...

The Human Cell Atlas Consortia just released its initial efforts in a series of articles. #MedSky #ScienceSky www.nature.com/immersive/d4...

Always looking forward to the omics work out of @ireneghobrial.bsky.social lab. A few of the intriguing ones at @ash-hematology.bsky.social #ASH24 #MyelomaSky #HemeSky ash.confex.com/ash/2024/web... ash.confex.com/ash/2024/web... ash.confex.com/ash/2024/web... ash.confex.com/ash/2024/web...

Excellent open-access #MMsm work in @AjHematology by Zabaleta @BrunoPaiva_UNAV et al! An important footnote for all the CAR-T vs bsAb efficacy debates: when stratified by MRD status, CAR-T and bsAbs do identically. Getting to MRD neg is what matters! onlinelibrary.wiley.com/doi/10.1002/...